NLS Collaboration

Kaiku Health and Roche are entering a strategic partnership in digital patient monitoring and management (DPMM). Kaiku Health and Roche aim to deploy digital tools to provide real-time symptom management by patients and Health Care Providers (HCPs), improve patient support, and provide personalized cancer care to cancer clinics and patients globally, they state. “Kaiku Health […]

The two companies have announced a collaboration to create a portfolio of novel research programmes to develop transformational medicines. The collaborators will explore opportunities to apply Flagship’s bioplatforms, an ecosystem that currently comprises 41 companies, to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these. A new […]

The two collaborators have signed an agreement with the aim to advance genomics and precision medicine and its implementation in healthcare. The joint partnership will focus on the development and implementation of innovative solutions and models to provide genomic-based precision medicine at a national level, state the collaborators. “Denmark and Sweden have many similarities in […]

We would like to thank our readers, subscribers and collaboration partners for a fruitful first quarter 2022, and we wish you all a relaxing – and safe – Easter! Nordic Life Science will be back April 19th to provide you with the latest news from our exciting life science industry! Until then, here are some […]

The two companies have signed a global commercial collaboration agreement in the field of radiation oncology. The collaboration enables them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy, they state. “Combining GE Healthcare’s imaging solutions with Elekta’s radiation therapy solutions will result in an even more compelling […]

Idogen has signed a strategic collaboration agreement with two contract research organizations, Danish Klifo and Finnish 4Pharma, which will together with Idogen run the clinical phase 1/2a study with IDO 8. IDO 8 is a new cell therapy for patients with severe hemophilia who have developed antibodies to their treatment with coagulation factor VIII. The […]